Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB-011 Caribou Biosciences (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CaMMouflage
  • Sponsors Caribou Biosciences

Most Recent Events

  • 06 Mar 2025 Planned primary completion date changed from 1 Feb 2025 to 1 May 2025.
  • 12 Jan 2025 According to a Caribou Biosciences media release, company plans to report dose escalation data on a minimum of 15 patients at active doses from this clinical trial in the first half of 2025
  • 06 Jul 2023 According to a Caribou Biosciences media release, company expects to provide updates from this study over the next six months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top